Macquarie Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-64,170
Closed -$26K 1724
2023
Q2
$26K Hold
64,170
﹤0.01% 1618
2023
Q1
$26K Hold
64,170
﹤0.01% 1662
2022
Q4
$28K Hold
64,170
﹤0.01% 1691
2022
Q3
$18K Hold
64,170
﹤0.01% 2245
2022
Q2
$23K Hold
64,170
﹤0.01% 2270
2022
Q1
$43K Hold
64,170
﹤0.01% 2194
2021
Q4
$83K Hold
64,170
﹤0.01% 1995
2021
Q3
$139K Hold
64,170
﹤0.01% 1872
2021
Q2
$175K Hold
64,170
﹤0.01% 1827
2021
Q1
$167K Hold
64,170
﹤0.01% 1757
2020
Q4
$178K Buy
+64,170
New +$187K ﹤0.01% 1701
2019
Q2
Sell
-108,125
Closed -$1.15M 1890
2019
Q1
$1.15M Buy
+108,125
New +$1.08M ﹤0.01% 1144

Macquarie Group's SIOX Position: Q3 2023 in Review

Macquarie Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2023, closing a stake of 64,170 shares — an estimated $26K sold.

Macquarie Group first reported a position in SIOX in Q1 2019 and held it in 12 quarters. The position peaked at $1.15M in Q1 2019. 0 funds tracked by Wall St. Rank hold SIOX as of Q3 2023.

  • Macquarie Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Macquarie Group sold 64,170 Sio Gene Therapies Inc. Common Stock shares in Q3 2023, an estimated $26K.
  • Macquarie Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2019 and held it in 12 quarters.
  • Macquarie Group's Sio Gene Therapies Inc. Common Stock position peaked at $1.15M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2023.

Based on Macquarie Group's 13F filing for Q3 2023, filed 14 Nov 2023.